Traumatic brain injury (TBI) is known as a "silent epidemic" ([@bibr26-1759091420910957]). Annually, approximately 54 to 60 million people suffer from TBI worldwide ([@bibr4-1759091420910957]). Survivors of TBI commonly live with neurocognitive deficits and physical disability and increased risk of neurodegenerative disease in the long term ([@bibr23-1759091420910957]). Unfortunately, no drug has been approved in Phase III of clinical trials for treating TBI ([@bibr28-1759091420910957]) because of complex pathogenesis, such as burst reactive oxygen species, increased glutamate levels, destroyed blood--brain barrier (BBB), uncontrolled neuroinflammation, and obliterated synapse ([@bibr16-1759091420910957]; [@bibr22-1759091420910957]; [@bibr15-1759091420910957]). Thus, the consensus of multitarget intervention was formed as its therapeutic principle. The multitarget property and advantageous efficacy of traditional Chinese medicine (TCM) in TBI has attracted much attention ([@bibr39-1759091420910957]) and has encouraged exploration of the integrative pathogenesis of TBI and the multitargeted pharmacomechanism of TCM through various omics technologies ([@bibr30-1759091420910957]; [@bibr43-1759091420910957]; [@bibr20-1759091420910957]).

Metabolomics is a common tool to uncover the pathogenesis of disease by reflecting the global metabolic profiling framework ([@bibr16-1759091420910957]). It is also employed to elucidate the molecular mechanism of TCM herbs ([@bibr38-1759091420910957]; [@bibr1-1759091420910957]). It is a crucial step in high-resolution analytics, together with chemometric tools, to derive an integrated picture of endogenous and xenobiotic metabolism ([@bibr9-1759091420910957]). The appropriate algorithm can provide deeper insights into the integrative mechanisms of specific diseases or therapeutic interventions. The current algorithms for metabolomics analysis primarily involve principal component analysis, partial least squares-discrimination analysis (PLS-DA), orthogonal PLS-DA, support vector machines (SVM), and random forests ([@bibr13-1759091420910957]). However, these conventional algorithms are not suitable for directly analyzing data at all times, and data mining is needed.

We proposed the variable iterative space shrinkage approach (VISSA) for variable selection in a previous study ([@bibr6-1759091420910957]). This approach iteratively and smoothly shrinks the variable space to obtain the best variable combination for modeling. First, the variable space is optimized in each step according to statistical information. Next, the variable space shrinks smoothly in VISSA by considering the variable combination eﬀects and avoiding the eliminating informative variables. Finally, the results are insensitive to parameters (e.g., sampling number or the ratio of selected models) and show improved prediction ability for calibration of data in VISSA relative to other variable selection methods ([@bibr6-1759091420910957]). VISSA could thus be a potential method for digging deep into metabolomics data.

Xuefu Zhuyu decoction (XFZY) is a classic TCM herbal formula in clinical practice. Recent basic and clinical evidence has demonstrated that it exerts neuroprotection against TBI ([@bibr35-1759091420910957]; [@bibr39-1759091420910957]). Its pharmacomechanisms involve synaptic regulation ([@bibr46-1759091420910957]), anti-inflammation ([@bibr39-1759091420910957]), antiapoptosis, and antioxidant effects ([@bibr45-1759091420910957]). Considering the successful application of metabolomics for uncovering TBI-related pathomechanisms ([@bibr3-1759091420910957]; [@bibr5-1759091420910957]; [@bibr14-1759091420910957]), we employed gas chromatography/mass spectrometry (GC-MS) for metabolomics to explore the mechanism of XFZY against TBI in our previous studies ([@bibr12-1759091420910957]; [@bibr43-1759091420910957]). In these studies, the PLS-DA model was successfully used to distinguish the groups (i.e., Sham, Vehicle, or XFZY group) on the 1st or 3rd day post-TBI ([@bibr12-1759091420910957]). However, the direct PLS-DA model was not capable of discriminating the XFZY treatment from the Vehicle group on the 7th day post-TBI (shown in [Figure 1](#fig1-1759091420910957){ref-type="fig"}).

![PLS-DA Model for Discrimination Between TBI and TBI Treated With XFZY.\
*Note*. In total, 44 metabolic variables were directly used to establish the PLS-DA model for distinguishing the Vehicle and XFZY groups. Its AUC was 59.24%.\
Vehicle = TBI rats treated with normal saline; XFZY = TBI rats treated with 9 g/kg Xuefu Zhuyu decoction; AUC = the area under receiver operating characteristic curve, evaluating the discrimination ability of classical models; PLS = partial least squares.](10.1177_1759091420910957-fig1){#fig1-1759091420910957}

The present study aimed to explore the VISSA-PLS-DA for GC-MS-based metabolomics to screen metabolic variables on the 7th day post-TBI and then to elucidate the multitargeted pharmacomechanism of XFZY against TBI. Thereby, it may provide a new method for studying TCM.

Materials and Methods {#sec1-1759091420910957}
=====================

Animals {#sec2-1759091420910957}
-------

Healthy male Sprague-Dawley (SD) rats (weight: 200 to 250 g) were supplied by the Laboratory Animal Research Center of Central South University, China. A controlled breeding room was used to house the rats with ad libitum access to normal standard chow diet and tap water. The temperature was maintained at 22°C to 25°C with 12 hr light/dark cycles and 50% ± 10% humidity. All rats adapted to these circumstances for at least 1 week. At the beginning of experiment, rats were fasted for 12 h with free access to water.

Model of TBI {#sec3-1759091420910957}
------------

The rat model of controlled cortical impact (CCI) was established using an electronic controlled pneumatic impact device (TBI 0310, Precision Systems & Instrumentation, Fairfax Station, VA) under 3% pentobarbital anesthesia (50 mg/kg). The parameters and procedures used were according to our previous research ([@bibr39-1759091420910957]). The body temperature of rats was maintained at 37.0 ± 0.5°C throughout the surgery.

Preparation of XFZY {#sec4-1759091420910957}
-------------------

According to the preparation method described in our previous study ([@bibr39-1759091420910957]), all herbal medicines in XFZY decoction (i.e., Semen *Persicae*, Flos *Carthami*, Radix *Angelicae Sinensis*, Radix *Rehmanniae*, Radix *Achyranthis Bidentatae*, Radix *Paeoniae Rubra*, Fructus *Aurantii*, Radix *Glycyrrhizae*, Rhizoma *Chuanxiong*, Radix *Platycodonis*, and Radix *Bupleuri*) were purchased from the Pharmacy of Xiangya Hospital of Central South University (Hunan Province, PR China). The previously mentioned 11 herbs of XFZY at a ratio of 8:6:6:6:6:4:4:4:3:3:2 were decocted using purified water. The decoctions were then used to prepare a lyophilized powder of XFZY according to our previous study ([@bibr39-1759091420910957]). Finally, 1 g of the freeze-dried powder contained 5.4 g of crude herbs. All powders were stored at 4°C before dissolving in distilled water for usage at a concentration of 1 g crude drugs/ml (*w/v*).

Experimental Design and Sample Collection {#sec5-1759091420910957}
-----------------------------------------

SD rats were randomly assigned to three groups: (a) Sham-operated group (Sham, *n* = 13): Rats underwent the same surgical procedures as CCI except no cerebral cortex trauma and gavage with an equal volume of normal saline (0.9% NaCl); (b) TBI + Vehicle (Vehicle, *n* = 15): Rats with CCI were intragastrically administered the same amount of normal saline vehicle; and (c) TBI + 9 g/kg XFZY group (XFZY, *n* = 22): Rats were orally given XFZY extract (9 g/kg body weight according to our previous study; [@bibr39-1759091420910957]) after CCI. Each group was administered once per day after TBI. On the 1st, 3rd, and 7th day post-TBI, neurological function test was performed for each group. On the 7th day, all rats were sacrificed for plasma collection after the neurological function tests. The plasma samples were centrifuged at 3,000 rpm at 4°C for 10 min. The supernatants were stored at --80°C until GC-MS-based metabolomics analysis.

Assessment of Neurological Function {#sec6-1759091420910957}
-----------------------------------

To assess neurological injury, the modified neurologic severity score (mNSS) was determined as in our previous study ([@bibr39-1759091420910957]). The motor (muscle status and abnormal movement); sensory (visual, tactile, and proprioceptive); and reflex abilities were tested on a scale of 0 to 18 (0 normal score; 18: maximal deficit score). On the 1st, 3rd, and 7th day post-TBI, the severity of neurological injury was evaluated by mNSS.

GC-MS Data Acquisition {#sec7-1759091420910957}
----------------------

Sample preparation was performed according to the procedures described previously ([@bibr40-1759091420910957]). Briefly, 100 µl plasma was mixed with 350 µl methanol, and 50 µl heptadecanoic acid (dissolved in methanol at a concentration of 1 mg/ml) was added as an internal standard. After vigorously vortexing for 1 min, the mixture was centrifuged at 16,000 rpm for 10 min at 4°C. The supernatant (400 µl) was transferred to a 5-ml glass centrifugation tube and evaporated to dryness under N~2~ gas. Then, 70 µl of methoxyamine hydrochloride solution (20 mg/ml in pyridine) was added to the residue and incubated for 60 min at 70°C. After methoximation, 100 µl of bistrifluoroacetamide derivatization agent was added to the residue and incubated for another 50 min at 70°C. The final solution was used for GC-MS analysis. In addition, 50 µl of each original sample was pooled to generate the quality control (QC), and 100 µl aliquots of this pooled sample were pretreated through the aforementioned process. One QC sample was injected after every five sample injections to monitor the stability of the experiment (Supplementary Figure S1).

All GC-MS analyses were performed using a gas chromatography instrument (Shimadzu GC2010A, Kyoto, Japan) coupled with a mass spectrometer (GC-MS-QP2010) with a constant flow rate of helium carrier gas at 1.0 ml/min. For each sample, 1.0 µl was injected into a DB-5ms capillary column (30 m × 0.25 mm i.d., film thickness 0.25 µm). The column temperature was initially maintained at 70°C for 4 min and was then increased to 300°C at a rate of 8°C/min. Subsequently, it was held for 3 min. The total run time was 35.75 min. Mass conditions were maintained as followed: ionization voltage, 70 eV; ion source temperature, 200°C; interface temperature, 250°C; full scan mode in the 35 to 800 amu mass ranges with 0.2 s scan velocity; detector voltage, 0.9 kV.

Identification of Endogenous Metabolites and Data Processing {#sec8-1759091420910957}
------------------------------------------------------------

GC-MS data of each plasma sample, including retention characteristics, peak intensities, and integrated mass spectra, were used for the analysis. First, the automated mass-spectral deconvolution and identification system (AMDIS software, National Institute of Standards and Technology, Gaithersburg, MD, USA) was employed to support the peak finding and deconvolution. Using NIST Mass Spectral Search Program Version 2.0 (the National Institute of Standards and Technology, Gaithersburg, MD, USA) and the characteristic ions, tentative identification of the structures of peaks-of-interest was supported by a similarity search of the NIST/EPA/NIH Mass Spectra Library (NIST05). Only metabolic features with a relative standard deviation for the relative peak areas of \<30% in QC samples were retained for subsequent data analysis ([@bibr11-1759091420910957]). In all, 44 metabolites were considered as the main endogenous metabolites, and 25 metabolites were identified by their corresponding chemical standards. The biochemical databases, including the Human Metabolome Database (<http://www.hmdb.ca/>; [@bibr37-1759091420910957]) and the Kyoto Encyclopedia of Genes and Genomes database (Kanehisa Labs, Japan, <http://www.genome.jp/kegg/>), were used to search and analyze each metabolite. The peak areas of metabolites were compared with those of the internal standards to provide a semiquantitative level for the metabolites. The peak areas were extracted using our custom scripts to generate a data matrix, in which the rows represent the samples and the columns correspond to peak/area ratios to the internal standard in the same chromatogram.

Data Analysis {#sec9-1759091420910957}
-------------

The data metrics of peak areas generated from metabolic profiles were analyzed by PLS-DA to establish any "groupings" with respect to the Vehicle, Sham, and XFZY group. In this study, the VISSA was employed to select the marked variables (metabolites; [@bibr6-1759091420910957]; [@bibr42-1759091420910957]): The first step was to create a binary matrix K × P for sampling; the second step was to carry out weighted binary matrix sampling based on the weights of variables obtained in Step 1 and create new submodels and then to calculate the mean root mean square error of cross-validation (RMSECV) of the best new submodels; the third step was to compare the mean RMSECV*~i~* with the mean RMSECV*~i~*~--1~; and the fourth step was to repeat Steps 1 to 3 using the candidate variable set and obtain a new variable set.

VISSA was calculated 500 times. The selected metabolites with high frequency (frequency ≥80% of total times) were regarded as potential biomarkers. After variable selection, PLS-DA models were established to distinguish between the Vehicle and XFZY groups (or Vehicle group vs. Sham group) on the 7th day. Then, 10-fold cross-validation was employed to select the optimal number of latent variables and to evaluate the predictive ability of the PLS-DA model. Permutation tests were employed to evaluate the reliability of the class model and were calculated 5,000 times. In a previous study, we proved that the area under receiver operating characteristic curve (AUC) was more sensitive than the correct rate to evaluate the discrimination ability of the classical models ([@bibr40-1759091420910957]). In this study, AUC was employed to evaluate the discriminant ability of model.

All data were expressed as "mean ± SD." The Mann--Whitney U test was employed to analyze each metabolite. The data from mNSS were analyzed by one-way analysis of variance with a least significant difference post hoc test using the SPSS 17.0 software package. Prism Graph Pad 5.0 software was used for graphing. *p* \< .05 was considered statistically significant. All programs of PLS-DA and other methods were coded in MATLAB 2010 for Windows, and all calculations were performed on an Intel Core i7 processor-based personal computer with 16G RAM.

Metabolic Pathway Analysis {#sec10-1759091420910957}
--------------------------

The Metabolic Pathway Analysis web tool (<http://www.metaboanalyst.ca/>) was used for pathway analysis as described previously ([@bibr41-1759091420910957]). The metabolites for discriminating between the XFZY group and Vehicle group were input for analysis. The pathway library was selected from "*Rattus norvegicus*." The default "hypergeometric test" was chosen for pathway enrichment analysis, and "relative-betweenness centrality" algorithms were selected for pathway topological analysis. Furthermore, 0.1 was considered as the impact-value threshold of pathway topology analysis to identify the relevant pathways ([@bibr41-1759091420910957]).

Results {#sec11-1759091420910957}
=======

Metabolic Profiling of Vehicle, Sham, and XFZY {#sec12-1759091420910957}
----------------------------------------------

GC-MS was used to determine 44 plasma metabolites (in [Table 1](#table1-1759091420910957){ref-type="table"}), which were involved in the metabolic processes of carbohydrates, amino acids, lipids, energy, organic acids, and urea. The Mann--Whitney U test was employed to calculate the significant difference for each metabolite (*p* \< .05 with a signed *t* value of 1). As shown in [Table 1](#table1-1759091420910957){ref-type="table"}, six metabolites including glycine, *trans*-4-hydroxyproline, phenylalanine, palmitic acid, linoleic acid, and oleic acid were significantly altered between the Vehicle and Sham group. Except for the significant decline of phenylalanine, the previously mentioned metabolites increased markedly in the Vehicle group compared with the Sham group. However, no significant difference for each metabolite was observed between the Vehicle group and XFZY group.

###### 

Metabolic Profiling of Vehicle, Sham, and Xuefu Zhuyu Decoction Groups.

![](10.1177_1759091420910957-table1)

  No.   Metabolites                                                                    Relative peak area                                                    
  ----- ------------------------------------------------------------------------------ -------------------- --------------- --------------- --- --- -------- -----------
  1     Pyruvic acid                                                                   0.134 ± 0.026        0.129 ± 0.020   0.131 ± 0.028   0   0   C00022   HMDB00243
  2     Lactic acid^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^             3.856 ± 0.993        3.840 ± 1.032   4.001 ± 1.067   0   0   C00186   HMDB00190
  3     L-alanine^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^               0.547 ± 0.091        0.549 ± 0.119   0.500 ± 0.143   0   0   C00041   HMDB00161
  4     Glycine^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^                 0.270 ± 0.045        0.325 ± 0.060   0.301 ± 0.088   0   1   C00037   HMDB00123
  5     Methylmalonic acid                                                             0.061 ± 0.009        0.059 ± 0.011   0.060 ± 0.014   0   0   C02170   HMDB00202
  6     N-acetylglycine                                                                0.072 ± 0.008        0.078 ± 0.019   0.073 ± 0.011   0   0   C05596   HMDB00532
  7     β-hydroxybutyric acid^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^   0.077 ± 0.023        0.085 ± 0.018   0.097 ± 0.040   0   0   C00989   HMDB00710
  8     L-valine^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^                0.211 ± 0.032        0.199 ± 0.051   0.193 ± 0.053   0   0   C00183   HMDB00883
  9     Urea                                                                           3.366 ± 0.599        3.363 ± 0.725   3.245 ± 0.696   0   0   C00086   HMDB00294
  10    L-isoleucine^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^            0.274 ± 0.038        0.264 ± 0.052   0.259 ± 0.048   0   0   C00407   HMDB00172
  11    L-proline^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^               0.316 ± 0.049        0.294 ± 0.073   0.264 ± 0.093   0   0   C00148   HMDB00162
  12    Succinic acid                                                                  0.025 ± 0.005        0.025 ± 0.005   0.026 ± 0.005   0   0   C00042   HMDB00254
  13    Glyceric acid                                                                  0.031 ± 0.012        0.030 ± 0.015   0.036 ± 0.012   0   0   C00116   HMDB00131
  14    Fumaric acid                                                                   0.015 ± 0.005        0.014 ± 0.005   0.016 ± 0.005   0   0   C00122   HMDB00134
  15    Serine^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^                  0.313 ± 0.038        0.303 ± 0.055   0.309 ± 0.067   0   0   C00065   HMDB00187
  16    Threonine^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^               0.444 ± 0.060        0.399 ± 0.065   0.435 ± 0.093   0   0   C00188   HMDB00167
  17    L-malic acid^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^            0.035 ± 0.009        0.036 ± 0.007   0.038 ± 0.009   0   0   C00497   HMDB00744
  18    Pyroglutamic acid^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^       0.574 ± 0.100        0.585 ± 0.082   0.595 ± 0.125   0   0   C01879   HMDB00267
  19    *trans*-4-hydroxyproline                                                       0.098 ± 0.014        0.114 ± 0.016   0.101 ± 0.021   0   1   C01157   HMDB00725
  20    Threonic acid^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^           0.033 ± 0.017        0.033 ± 0.014   0.038 ± 0.020   0   0   --       HMDB00943
  21    Creatinine^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^              0.165 ± 0.048        0.135 ± 0.039   0.115 ± 0.053   0   0   C00791   HMDB00562
  22    α-ketoglutaric acid                                                            0.013 ± 0.006        0.015 ± 0.003   0.015 ± 0.004   0   0   C00026   HMDB00208
  23    Ornithine                                                                      0.069 ± 0.021        0.070 ± 0.032   0.064 ± 0.030   0   0   C00077   HMDB03374
  24    Glutamic acid^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^           0.101 ± 0.031        0.087 ± 0.026   0.095 ± 0.025   0   0   C00025   HMDB00148
  25    Phenylalanine^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^           0.085 ± 0.017        0.072 ± 0.013   0.075 ± 0.018   0   1   C00079   HMDB00159
  26    Aspartic acid                                                                  0.041 ± 0.014        0.040 ± 0.013   0.034 ± 0.011   0   0   C00049   HMDB00191
  27    Ribitol                                                                        0.064 ± 0.030        0.053 ± 0.021   0.059 ± 0.021   0   0   C00474   HMDB00508
  28    Lysine                                                                         0.06 ± 0.0370        0.088 ± 0.042   0.100 ± 0.074   0   0   C00047   HMDB00182
  29    Glutamine^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^               0.032 ± 0.021        0.029 ± 0.013   0.034 ± 0.016   0   0   C00064   HMDB00641
  30    Citric acid^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^             0.097 ± 0.039        0.096 ± 0.028   0.093 ± 0.033   0   0   C00158   HMDB00094
  31    1,5-anhydro-d-ghlcitol                                                         0.143 ± 0.040        0.137 ± 0.031   0.127 ± 0.019   0   0   --       HMDB41561
  32    D-fructose                                                                     0.053 ± 0.012        0.051 ± 0.018   0.053 ± 0.026   0   0   C00095   HMDB00660
  33    Galactose                                                                      0.097 ± 0.020        0.104 ± 0.034   0.134 ± 0.050   0   0   C01582   HMDB00143
  34    D-glucose^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^               9.520 ± 1.412        9.351 ± 1.977   8.867 ± 1.183   0   0   C00031   HMDB00122
  35    L-tyrosine^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^              0.113 ± 0.038        0.103 ± 0.034   0.095 ± 0.035   0   0   C00082   HMDB00158
  36    Palmitic acid^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^           0.419 ± 0.081        0.533 ± 0.136   0.598 ± 0.170   0   1   C00249   HMDB00220
  37    Tryptophan                                                                     0.009 ± 0.004        0.012 ± 0.006   0.013 ± 0.006   0   0   C00078   HMDB00929
  38    Myo-inositol                                                                   0.139 ± 0.038        0.132 ± 0.030   0.143 ± 0.035   0   0   C00137   HMDB00211
  39    Heptadecanoic acid                                                             0.011 ± 0.003        0.011 ± 0.005   0.010 ± 0.004   0   0   --       HMDB02259
  40    Linoleic acid^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^           0.268 ± 0.057        0.322 ± 0.076   0.332 ± 0.126   0   1   C01595   HMDB00673
  41    Oleic acid^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^              0.280 ± 0.070        0.394 ± 0.085   0.428 ± 0.114   0   1   C00712   HMDB00207
  42    Stearic acid^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^            0.324 ± 0.074        0.327 ± 0.093   0.313 ± 0.117   0   0   C01530   HMDB00827
  43    Arachidonic acid^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^        0.093 ± 0.028        0.101 ± 0.017   0.103 ± 0.045   0   0   C00219   HMDB01043
  44    Cholesterol^[a](#table-fn2-1759091420910957){ref-type="table-fn"}^             0.460 ± 0.140        0.524 ± 0.144   0.580 ± 0.163   0   0   C00187   HMDB00067

*Note*. Relative peak area of 44 metabolites is presented as the mean ± SD. KEGG = Kyoto Encyclopedia of Genes and Genomes; HMDB = Human Metabolome Database.

Identified by standard substances.

Metabolic Characteristics of XFZY-Treated TBI Rats Compared With TBI Rats {#sec13-1759091420910957}
-------------------------------------------------------------------------

Owing to no significant difference for each metabolite in the XFZY group relative to the Vehicle group, the PLS-DA algorithm was directly used to establish a discriminant model for distinguishing these. As shown in [Figure 1](#fig1-1759091420910957){ref-type="fig"}, the AUC of this model was 59.24%, indicating the failure of modeling with poor discriminant ability.

To establish an ideal discriminant model, the VISSA-PLS-DA model was employed ([Figure 2](#fig2-1759091420910957){ref-type="fig"}). First, the frequency of metabolites was calculated by VISSA for 500 times. Then, 10 metabolites were selected by VISSA as shown in [Figure 2A](#fig2-1759091420910957){ref-type="fig"}, namely, threonine, *trans*-4-hydroxyproline, threonic acid, creatinine, phenylalanine, aspartic acid, 1,5-anhydro-sorbitol, galactose, tryptophan, and stearic acid. Next, a PLS-DA model for distinguishing Vehicle and XFZY group was established according to the previously mentioned 10 metabolites ([Figure 2B](#fig2-1759091420910957){ref-type="fig"}). Its AUC was 93.64%. These results suggested super discriminant ability for distinguishing rats treated with XFZY from TBI rats. Threonine, *trans*-4-hydroxyproline, threonic acid, creatinine, phenylalanine, aspartic acid, 1,5-anhydro-sorbitol, galactose, tryptophan, and stearic acid were selected as the potential metabolites altered by XFZY in TBI.

![VISSA-PLS-DA Model for Discrimination Between TBI and TBI Treated With XFZY.\
*Note*. The variable iterative space shrinkage approach (VISSA) was first employed to select the marked variables from 44 metabolic variables. Then, the metabolic variables with high frequency (≥400) were used to establish the PLS-DA model for distinguishing the Vehicle and XFZY groups. (a) Frequency of each metabolite in the VISSA algorithm. The red bars are metabolites with high frequency. 1: threonine; 2: *trans*-4-hydroxyproline; 3: threonic acid; 4: creatinine; 5: phenylalanine; 6: aspartic acid; 7: 1,5-anhydro-d-ghlcitol; 8:galactose; 9: tryptophan; and 10: stearic acid. (b) PLS-DA model between the Vehicle and XFZY group. Its AUC was 93.64%.\
Vehicle = TBI rats treated with normal saline; XFZY = TBI rats treated with 9 g/kg Xuefu Zhuyu decoction; AUC = the area under receiver operating characteristic curve, evaluating the discrimination ability of classical models; PLS = partial least squares.](10.1177_1759091420910957-fig2){#fig2-1759091420910957}

Metabolic Characteristics of TBI Rats Compared With Sham-TBI {#sec14-1759091420910957}
------------------------------------------------------------

Analogously, the VISSA-PLS-DA model was used to discriminate the Vehicle group from the Sham group ([Figure 3](#fig3-1759091420910957){ref-type="fig"}). The frequency of metabolites was calculated by VISSA for 500 times, and 5 metabolites with high frequency were selected ([Figure 3A](#fig3-1759091420910957){ref-type="fig"}), that is, threonine, *trans*-4-hydroxyproline, creatinine, fumaric acid, and oleic acid. Next, these metabolites were employed to establish a PLS-DA model ([Figure 3B](#fig3-1759091420910957){ref-type="fig"}). The value of AUC was 89.74%, suggesting high discriminant ability. The changes in threonine, *trans*-4-hydroxyproline, creatinine, fumaric acid, and oleic acid were able to distinguish TBI rats and Sham-TBI.

![VISSA-PLS-DA Model for Discrimination Between TBI and Sham-TBI.\
*Note*. The variable iterative space shrinkage approach (VISSA) was first employed to select the marked variables from 44 metabolic variables. Then, the metabolic variables with high frequency (≥400) were used to establish the PLS-DA model for distinguishing the Vehicle and Sham groups. (a) Frequency of each metabolite in the VISSA algorithm. The red bars were metabolites with high frequency. 1: fumaric acid; 2: threonine; 3: *trans*-4-hydroxyproline; 4: creatinine; and 5: oleic acid. (b) PLS-DA model between the Vehicle and Sham group. Its AUC was 89.74%.\
Vehicle = TBI rats treated with normal saline; Sham = rats without TBI treated with normal saline; AUC = the area under receiver operating characteristic curve, evaluating the discrimination ability of classical models; PLS = partial least squares.](10.1177_1759091420910957-fig3){#fig3-1759091420910957}

Direct Metabolic Targets of XFZY Against TBI {#sec15-1759091420910957}
--------------------------------------------

To elucidate the direct effective mechanism of XFZY on TBI, an intersection of two previously mentioned metabolic panels was executed. As shown in [Figure 4A](#fig4-1759091420910957){ref-type="fig"}, threonine, *trans*-4-hydroxyproline, and creatinine were identified as the direct metabolic targets intervened by XFZY. Following CCI, the levels of threonine and creatinine in plasma were decreased ([Figure 4B, 4D](#fig4-1759091420910957){ref-type="fig"}), whereas *trans*-4-hydroxyproline was upregulated on the 7th day ([Figure 4C](#fig4-1759091420910957){ref-type="fig"}). After treatment with 9 g/kg XFZY, the decreased threonine was recovered close to the baseline of the Sham group ([Figure 4B](#fig4-1759091420910957){ref-type="fig"}), and the increase in *trans*-4-hydroxyproline was reversed on the 7th day ([Figure 4C](#fig4-1759091420910957){ref-type="fig"}). Interestingly, rats treated with XFZY showed further reduced plasma levels of creatinine compared with the Vehicle group ([Figure 4D](#fig4-1759091420910957){ref-type="fig"}).

![Effects of XFZY on Directly Modulating the Target Metabolites of TBI.\
*Note*. (a) The intersection of two metabolic panels including threonine, *trans*-4-hydroxyproline, and creatinine was identified. The left ellipse represents the metabolic panels for discrimination between the Vehicle and Sham group. The right ellipse represents metabolic panels for discrimination between the Vehicle and XFZY group. The Scatter diagram, respectively, represents the plasma changes of threonine (b), *trans*-4-hydroxyproline (c), and creatinine (d) in the Sham, Vehicle, and XFZY groups on the 7th day post-TBI. (Data are presented as the mean ± SD, \**p* \< .05 vs. the Sham group.)\
Vehicle = TBI rats treated with normal saline; Sham = rats without TBI given with normal saline; XFZY = TBI rats treated with 9 g/kg Xuefu Zhuyu decoction.](10.1177_1759091420910957-fig4){#fig4-1759091420910957}

Metabolic Pathways Intervened by XFZY in TBI {#sec16-1759091420910957}
--------------------------------------------

The 10 previously mentioned metabolites for discriminating between the XFZY group and Vehicle group were analyzed using Metabolic Pathway Analysis. The enriched metabolic pathways were considered as the metabolic pathways targeted by XFZY in TBI rats. As shown in [Figure 5](#fig5-1759091420910957){ref-type="fig"}, five metabolic pathways were selected as the potential metabolic pathways regulated by XFZY. These pathways included phenylalanine, tyrosine, and tryptophan biosynthesis; phenylalanine metabolism; galactose metabolism; alanine, aspartate, and glutamate metabolism; and tryptophan metabolism.

![Summary of Enriched Metabolic Pathways Analysis Using MetPA.\
*Note*. MetPA was used to analyze 10 screened metabolites for discriminating the Vehicle group and XFZY group, and 5 metabolic pathways of importance were enriched: (a) phenylalanine, tyrosine, and tryptophan biosynthesis; (b) phenylalanine metabolism; (c) galactose metabolism; (d) alanine, aspartate, and glutamate metabolism; and (e) tryptophan metabolism.](10.1177_1759091420910957-fig5){#fig5-1759091420910957}

Improvement of Neurological Function Induced by XFZY in TBI {#sec17-1759091420910957}
-----------------------------------------------------------

To determine the efficacy of XFZY against TBI, the mNSS test was performed to assess the recovery of impaired neurological function on the 1st, 3rd, and 7th day post-TBI. In [Figure 6](#fig6-1759091420910957){ref-type="fig"}, neurologic deficits were observed at predetermined timepoints from the onset of CCI, which was similar to our previous study ([@bibr39-1759091420910957]). Compared with the Vehicle group, treatment with XFZY (9 g/kg) significantly contributed to the recovery of neurological deficiency, as shown by decreased mNSS scores ([Figure 6](#fig6-1759091420910957){ref-type="fig"}). Furthermore, significant improvement of neurological functions was observed from the 3rd to 7th day post-TBI.

![mNSS After TBI or Sham Injury or TBI Treated With XFZY.\
*Note*. The mNSS test was performed to assess neurological function. Following CCI, significant increases of mNSS scores in the Vehicle group (*n* = 15) relative to the Sham group (*n* = 13) were observed from the 1st to 7th day post-TBI. Treatment with 9 g/kg XFZY (*n* = 22) significantly lowered the mNSS scores on the 3rd and 7th day compared with those in the Vehicle group. (Data are analyzed by one-way analysis of variance and presented as the mean ± SD. \**p* \< .05 vs. Vehicle group; ^\#^*p* \< .05 vs. XFZY group.)\
Vehicle = TBI rats treated with normal saline; Sham = rats without TBI treated with normal saline; XFZY = TBI rats treated with 9 g/kg Xuefu Zhuyu decoction; TBI = traumatic brain injury; mNSS = modified neurologic severity score.](10.1177_1759091420910957-fig6){#fig6-1759091420910957}

Discussion {#sec18-1759091420910957}
==========

The primary finding of this study is that the VISSA-PLS-DA model of GC/MS-based metabolomics is a valid method to unravel the multitargeted mechanisms of XFZY against TBI. Following this method, we found that XFZY exerted protective effects on TBI in terms of metabolic mechanisms. Threonine, *trans*-4-hydroxyproline, and creatinine were identified as the direct metabolic targets of XFZY against TBI, with a concomitant rescue of impaired neurological function induced by XFZY. In addition, neuroprotection of XFZY against TBI might involve the regulation of phenylalanine, tyrosine, and tryptophan biosynthesis; phenylalanine metabolism; galactose metabolism; alanine, aspartate, and glutamate metabolism; and tryptophan metabolism.

Our observation that alanine, aspartate, and glutamate metabolism was regulated by XFZY against TBI on the 7th day is consistent with our previous findings in metabolomics on the 1st and 3rd day post-TBI ([@bibr12-1759091420910957]). These similar results support the validity of VISSA-PLS-DA to screen metabolic variables. Simultaneously, there were some differences relative to previous study ([@bibr12-1759091420910957]), which may be attributed to the changes in plasma levels of metabolites with time. Intriguingly, these different metabolites including threonine, trans-4-hydroxy-L-proline, and creatinine possess its clinical significance in TBI disease.

Threonine is an essential amino acid. Its phosphorylation is one of the most prevalent posttranslational modifications that mediates diverse cellular functions ([@bibr24-1759091420910957]). Upon onset of TBI, the activities of various serine-threonine kinases contribute to the progression of TBI pathology via phosphorylating the threonine residue of targeted proteins. For instance, the protein kinase B (Akt)/protein kinase C is related to glutamate hyperexcitability ([@bibr10-1759091420910957]), nemo-like kinase is related to the neuronal apoptosis ([@bibr18-1759091420910957]), and mammalian target of rapamycin (mTOR) is involved in the neurocognitive outcome following TBI ([@bibr21-1759091420910957]; [@bibr25-1759091420910957]). In our results, the changes in threonine levels in TBI rats may partly reflect the influence of the biosynthesis process of serine/threonine kinases following TBI. This effect may be further involved in the activity of serine/threonine kinases. The reverse of threonine level induced by treatment with XFZY may also refer to these processes. These speculations have been partly supported by our previous findings that the neuroprotection of XFZY against TBI involved changes in serine/threonine kinases, that is, Akt-mTOR ([@bibr39-1759091420910957]).

*Trans*-4-hydroxy-L-proline is an important marker to assess the content of collagen in biological samples ([@bibr36-1759091420910957]). Of these, collagen IV is one of the main components of the basal lamina, which maintains the function of the BBB ([@bibr47-1759091420910957]). Hence, the increased plasma level of *trans*-4-hydroxy-L-proline may be induced by the disruption of BBB. Treatment with XFZY attenuated this upregulation, suggesting that the neuroprotective effect of XFZY against TBI may involve functional improvement of the BBB. However, bone resorption after skull fracture also results in the release of collagens ([@bibr33-1759091420910957]), causing an increase in *trans*-4-hydroxy-L-proline level. The decreased *trans*-4-hydroxy-L-proline induced by XFZY may also result from healing of the traumatic skull. Further studies are needed for evidence to exclude this interference.

Creatinine is a by-product of muscle metabolism. Considering its constant generation in the living body and excretion in kidneys, its clearance (CL~CR~) is used as an indicator for assessing renal function. Mounting evidence has shown that renal clearance of creatinine is augmented following TBI ([@bibr31-1759091420910957]; [@bibr8-1759091420910957]; [@bibr32-1759091420910957]). This physiological link between the brain and kidney may involve a relationship between cerebrovascular autoregulation and CL~CR~. The reasons are as follows: First, a higher CL~CR~ value in TBI was correlated with better outcome ([@bibr8-1759091420910957]); furthermore, one potential mechanism from atrial natriuretic peptide (ANP) supports this relationship. The ANP is excreted through the cerebrovascular autoregulation system; it then exerts neuroprotection against edema formation and enhances CL~CR~ by elevating the permeability of glomerular capillary beds ([@bibr32-1759091420910957]). The plasma level of creatinine thus reflects the ANP level to some extent. In line with these reports, we found deceased plasma level of creatinine on the 7th day post-TBI, suggesting an elevated renal clearance. After treatment with XFZY, lower levels of creatinine accompanying improved neurological function may contribute to the upregulation of ANP, which needs to be demonstrated in a further experiment.

Apart from directly targeting metabolites, the protection of XFZY against TBI may be exerted through regulating metabolic pathways. Three metabolites (phenylalanine, tryptophan, and tyrosine) were found to influence the changes in intracranial pressure and cerebral oxygen consumption (SjvO~2~) following TBI ([@bibr34-1759091420910957]). The increased plasma phenylalanine levels were beneficial for decreasing intracranial pressure and reducing cerebral oxygen consumption ([@bibr34-1759091420910957]). In our study, treatment with XFZY increased the phenylalanine level post-TBI and contributed to the recovery of neurological function. These results indicate that the neuroprotection of XFZY may involve regulation of the three metabolic pathways relative to phenylalanine (including phenylalanine, tyrosine, and tryptophan biosynthesis; the phenylalanine metabolism; and the tryptophan metabolism). Moreover, our previous metabolomics study in TBI patients with cognitive impairment showed a disorder in galactose metabolism ([@bibr41-1759091420910957]). XFZY regulated galactose metabolism in present study, which partly supports its neuroprotective role in TBI. In addition, a profound, long-lasting imbalance of alanine, aspartate, and glutamate metabolism was observed in an animal model of TBI (Amorini et al.,2017). In our study, the intervention of XFZY in this metabolic disorder may contribute to its protective mechanism. Therefore, the aforementioned evidence suggests that XFZY exerts neuroprotection against TBI through multi-intervention of metabolic pathways.

The previously mentioned clinical significance of the metabolomics results indicates that the VISSA-PLS-DA model is reasonable and scientific. Meanwhile, in terms of chemometric analysis, the VISSA-PLS-DA analytical model is more preponderant than the single PLS-DA model to discriminate two datasets. VISSA is an optimization algorithm for the selection of variable, based on weighted binary matrix sampling and model population analysis strategies ([@bibr6-1759091420910957]). Its advantages include overcoming the uncertainty of a single model, generating synergistic/combination effects, and avoiding the elimination of important variables by mistake during the optimization process ([@bibr27-1759091420910957]). Up to now, it was mainly employed to deal with complex NIR datasets. Moreover, compared with some mainstream methods of multivariate data analysis, including iteratively retaining informative variables, competitive adaptive reweighted sampling, and Monte Carlo uninformative variable elimination, VISSA provides the lowest degree of overfitting ([@bibr29-1759091420910957]), as well as better prediction ability for the calibration of NIR data ([@bibr6-1759091420910957]). Besides, novel algorithms developed from VISSA, such as iVISSA, VISSA-iPLS, and VISSA-ABC-SVM, also showed better performance for the analysis of NIR data ([@bibr7-1759091420910957]; [@bibr27-1759091420910957]; [@bibr17-1759091420910957]). In our study, the VISSA algorithm improved the performance of PLS-DA model by removing the uninformative variables and interfering variables using shrinkage of variable space. In the beginning, we directly used 44 metabolites to establish the PLS-DA model for discriminating the Vehicle and XFZY groups. Its AUC was 59.24%. However, after VISSA selected 10 metabolites, the AUC value of the VISSA-PLS-DA model reached 93.64%. These results suggest the superiority of the VISSA-PLS-DA discriminative model.

However, compared with our previous research ([@bibr12-1759091420910957]), there are several different results in this metabolomics study: the direct metabolic targets of XFZY against TBI, and the metabolic pathways intervened by XFZY, except for alanine, aspartate, and glutamate metabolism. These differences could originate from different points-in-time post-TBI or the number of analytical metabolites (i.e., adding seven metabolites and removing one metabolite in this study relative to our previous study). In addition, further molecular biology experiments are needed to determine whether *trans*-4-hydroxy-L-proline is involved in the recovery of BBB or in the healing of traumatic skull, as well as whether XFZY provides a neuroprotective role in TBI via upregulating the ANP levels in blood circulation. Analogously, whether the three metabolites (threonine, *trans*-4-hydroxyproline, and creatinine) are specific targets of XFZY needs further investigation.

In summary, metabolomics based on the VISSA-PLS-DA model successfully uncovered the multitargeted mechanisms of XFZY against TBI, which are involved in modulating three direct metabolic targets (threonine, *trans*-4-hydroxyproline, and creatinine) and intervening in five metabolic pathways (phenylalanine, tyrosine, and tryptophan biosynthesis; phenylalanine metabolism; galactose metabolism; alanine, aspartate, and glutamate metabolism; and tryptophan metabolism). These findings indicate that metabolomics coupled with the VISSA-PLS-DA model is a valuable tool for identification of the holistic molecular mechanisms involved in the effects of TCM.
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